You are here

VANGUARD THERAPEUTICS, INC.

Company Information
Address 108 EAGLE TRACE DR
Half Moon Bay, CA, 94019-2286


Information

DUNS: 961937666

# of Employees: 4


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy

    Amount: $1,675,225.00

    Abstract Sickle cell disease SCD is a poorly treated inherited debilitating condition for which Vanguard Therapeutics Inc is developing a promising new long term oral therapy A dire need exists ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Improved Oral P selectin Blocker for Prophylactic Sickle Cell Disease Therapy

    Amount: $1,992,324.00

    Abstract Sickle cell disease SCD is a poorly treated inherited debilitating condition for which Vanguard Therapeutics Inc is developing a promising new long term oral therapy A dire need exists ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  3. Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy

    Amount: $226,033.00

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dir ...

    SBIRPhase I2014Department of Health and Human Services
  4. Reliable Assays for Pentosan Polysulfate Sodium

    Amount: $335,702.00

    DESCRIPTION provided by applicant Sickle cell disease SCD remains a poorly treated disease Based on evidence that endothelial P selectin is central to the abnormal microvascular blood flow in SC ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government